Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724715 | 0.67 | NOTUM (0.31) | — | |
| SCHEMBL12520764 | 0.64 | SIGMAR1 (0.32) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL5021296 | 0.63 | SIGMAR1 (0.50) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL157184 | 0.62 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL4077470 | 0.62 | SIGMAR1 (0.95) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL19840372 | 0.62 | SIGMAR1 (0.95) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL20682524 | 0.62 | SIGMAR1 (0.95) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL7834708 | 0.61 | — | — | |
| SCHEMBL8890 | 0.60 | TSHR (0.48) | SIGMAR1 | |
| SCHEMBL2871422 | 0.60 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2024046370-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITORS, AND PREPARATION AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-03-07 | — | — | WO | claimed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | claimed |
| US-5674880-A | ANTIINFLAMMATORY AGENT | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-10-07 | — | — | US | claimed |
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | CARLSSON JENS (SE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024125600-A1 | HETEROCYCLIC COMPOUNDS ACTING AS KRAS INHIBITORS, PREPARATION THEREFOR AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117751105-A | Substituted hydantoin compounds, process for their preparation and their use in the treatment and/or prophylaxis of coronavirus diseases | J·卡尔松 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024046370-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITORS, AND PREPARATION AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-03-07 | — | — | WO | disclosed |
| EP-4329883-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | Carlsson, Jens (SE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4028401-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| CN-117003739-A | Nitrogen-containing heterocyclic compound, preparation method and application thereof | 安徽中医药大学 | 2023-11-07 | — | — | CN | disclosed |
| EP-2502909-A1 | AMINOPYRIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| US-6080790-A | SELECTIVE AND POTENT INHIBITORS OF PHOSPHODIESTERASE IV AND ARE USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY DISEASES AND THE ALLEVIATION OF CONDITIONS ASSOCIATED WITH CENTRAL NERVOUS MALFUNCTION | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-06-27 | — | — | US | disclosed |
| EP-0618889-B1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 1998-12-30 | — | — | EP | disclosed |
| US-5674880-A | ANTIINFLAMMATORY AGENT | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-10-07 | — | — | US | disclosed |
| US-5491147-A | PHOSPHODIESTERASE IV INHIBITORS | CELLTECH, LIMITED (GB) | 1996-02-13 | — | — | US | disclosed |
| EP-0618889-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1994010118-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | SIGMAR1 1994/4885NOS3 4657/4885NOS1 4712/4885 |
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | FURIN, ACE, PEPD | SIGMAR1 2904/4885NOS3 1315/4885NOS1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.